For instance, the responses to inhibitors targeting the B cell receptor (BCR) components Bruton’s tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), and spleen tyrosine kinase (SYK) were highly correlated across the 184 CLL samples and showed a distinctive profile, which was shared with inhibitors of kinases downstream of the BCR, including AKT, LYN, and SRC. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.